Effect of Central Sympathoinhibition With Moxonidine on Sympathetic Nervous Activity in Polycystic Ovary Syndrome—A Randomized Controlled Trial

Effect of Central Sympathoinhibition With Moxonidine on Sympathetic Nervous Activity in Polycystic Ovary Syndrome—A Randomized Controlled Trial

Sympathetic nervous system (SNS) activity is increased in polycystic ovary syndrome (PCOS). Moxonidine is a centrally acting sympatholytic drug with known beneficial effects on hypertension, insulin sensitivity, dyslipidemia and inflammation. In this double-blind placebo controlled randomized clinic...

Full description

Bibliographic Details
Main Authors: Soulmaz Shorakae, Elisabeth A. Lambert, Eveline Jona, Carolina Ika Sari, Barbora de Courten, John B. Dixon, Gavin W. Lambert, Helena J. Teede
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-10-01
Series:Frontiers in Physiology
Subjects:
polycystic ovary syndrome
sympathetic nervous system
insulin resistance
moxonidine
randomized controlled trial
Online Access:https://www.frontiersin.org/article/10.3389/fphys.2018.01486/full

Internet

https://www.frontiersin.org/article/10.3389/fphys.2018.01486/full

Similar Items